C.R. Bard, Inc. (NYSE:BCR) has been given a consensus rating of “Hold” by the twelve ratings firms that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, eight have given a hold recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $308.60.

BCR has been the topic of several research reports. BMO Capital Markets reaffirmed a “hold” rating and issued a $317.00 target price on shares of C.R. Bard in a research report on Tuesday, July 11th. Zacks Investment Research lowered C.R. Bard from a “buy” rating to a “hold” rating in a research report on Monday, July 17th. BidaskClub lowered C.R. Bard from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 19th. Jefferies Group LLC reissued a “hold” rating on shares of C.R. Bard in a research report on Thursday, August 3rd. Finally, Needham & Company LLC reissued a “hold” rating on shares of C.R. Bard in a research report on Thursday, October 26th.

COPYRIGHT VIOLATION NOTICE: “C.R. Bard, Inc. (BCR) Receives Consensus Recommendation of “Hold” from Brokerages” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/11/07/c-r-bard-inc-bcr-receives-consensus-recommendation-of-hold-from-brokerages.html.

C.R. Bard (NYSE:BCR) traded up $0.53 on Thursday, reaching $334.39. 535,030 shares of the company’s stock traded hands, compared to its average volume of 461,303. The company has a current ratio of 1.72, a quick ratio of 1.37 and a debt-to-equity ratio of 0.57. The firm has a market capitalization of $24,335.84, a price-to-earnings ratio of 28.83, a PEG ratio of 2.55 and a beta of 0.53. C.R. Bard has a 12 month low of $203.63 and a 12 month high of $335.84.

C.R. Bard (NYSE:BCR) last issued its earnings results on Wednesday, October 25th. The medical instruments supplier reported $3.02 earnings per share for the quarter, topping the consensus estimate of $2.96 by $0.06. The business had revenue of $989.80 million for the quarter, compared to analyst estimates of $990.64 million. C.R. Bard had a return on equity of 48.28% and a net margin of 14.75%. The business’s quarterly revenue was up 5.1% on a year-over-year basis. During the same period last year, the company posted $2.64 EPS. research analysts forecast that C.R. Bard will post 11.89 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 29th. Shareholders of record on Friday, December 8th will be given a $0.26 dividend. This represents a $1.04 annualized dividend and a yield of 0.31%. The ex-dividend date is Thursday, December 7th. C.R. Bard’s dividend payout ratio (DPR) is presently 13.70%.

In other news, insider Timothy P. Collins sold 8,388 shares of C.R. Bard stock in a transaction dated Monday, October 9th. The stock was sold at an average price of $322.00, for a total transaction of $2,700,936.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider John P. Groetelaars sold 23,687 shares of C.R. Bard stock in a transaction dated Thursday, August 10th. The stock was sold at an average price of $318.73, for a total value of $7,549,757.51. Following the sale, the insider now directly owns 31,445 shares in the company, valued at $10,022,464.85. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 181,845 shares of company stock worth $59,061,051. Corporate insiders own 0.80% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in BCR. Farallon Capital Management LLC purchased a new stake in shares of C.R. Bard during the second quarter worth about $463,101,000. Alpine Associates Management Inc. acquired a new position in C.R. Bard in the second quarter worth about $265,663,000. Pentwater Capital Management LP acquired a new position in C.R. Bard in the second quarter worth about $139,088,000. York Capital Management Global Advisors LLC acquired a new position in C.R. Bard in the second quarter worth about $122,678,000. Finally, CNH Partners LLC acquired a new position in C.R. Bard in the second quarter worth about $116,100,000. 79.04% of the stock is currently owned by institutional investors and hedge funds.

C.R. Bard Company Profile

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Analyst Recommendations for C.R. Bard (NYSE:BCR)

Receive News & Stock Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related stocks with our FREE daily email newsletter.